Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two topical antimicrobial agents, mafenide acetate (marketed as Sulfamylon) and silver nitrate. Both are used primarily in the management of burn wounds to prevent and treat infections. Mafenide acetate is a synthetic sulfonamide derivative with broad-spectrum antibacterial activity, particularly effective against gram-negative organisms such as Pseudomonas aeruginosa. It penetrates burn eschar and exerts its effect on both viable and nonviable tissue, making it useful for deep burns[1][2]. Silver nitrate acts as an anti-infective agent by releasing silver ions that denature proteins and disrupt microbial cell walls, providing broad-spectrum antimicrobial coverage[6]. The combination may be used sequentially or together in specialized protocols for severe burns or wounds at high risk of infection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulfamylon + silver nitrate.